TLDR Most European physicians know the risks and safe use of Cyproterone acetate, but few remember receiving official safety communications.
The study aimed to assess European physicians' awareness of the updated safety information regarding the use of Cyproterone acetate (CPA) monotherapy, specifically the risk of meningioma with increased cumulative doses. A web-based survey was conducted with 613 physicians across five European countries who had prescribed CPA in the past year. The results showed that 85% of physicians were aware that CPA should be prescribed at the lowest effective dose, 75% knew about the increased risk of meningioma with higher cumulative doses, and 73% understood that CPA treatment must cease if a patient is diagnosed with meningioma. However, only 40% recalled receiving the Direct Healthcare Professional Communication (DHPC), and 42% recalled receiving the revised summary of product characteristics (SmPC). Despite the low recall of these communications, the majority of physicians were informed about the risks and necessary precautions when prescribing CPA.
59 citations,
February 2021 in “BMJ” High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.
12 citations,
August 2017 in “Pharmaceutical medicine” Most doctors know the thrombosis risk with Cyproterone/Ethinylestradiol, but some lack details on less common risks and patient instructions; educational materials are underused but useful.
88 citations,
May 2011 in “British Journal of Clinical Pharmacology” High doses of cyproterone acetate are linked to an increased risk of developing meningioma.
46 citations,
September 2016 in “Clinical, Cosmetic and Investigational Dermatology” Hormonal treatments are effective for severe or persistent acne and should be used with other acne therapies, considering potential side effects.
15 citations,
September 2021 in “Frontiers in Endocrinology” Hormone therapy increases the risk of heart-related issues in transgender women and may affect heart health in transgender men.
88 citations,
May 2011 in “British Journal of Clinical Pharmacology” High doses of cyproterone acetate are linked to an increased risk of developing meningioma.
34 citations,
November 2017 in “Gynecological Endocrinology” A transwoman developed a brain tumor after nine years of hormone therapy, suggesting a possible link between the treatment and tumor development.
5 citations,
June 2021 in “Journal of neurology, neurosurgery and psychiatry” Taking high doses of Cyproterone acetate significantly increases the risk of meningioma in females.
